Summary: The protein encoded by this gene is a member of the ELAVL family of RNA-binding proteins that contain several RNA recognition motifs, and selectively bind AU-rich elements (AREs) found in the 3' untranslated regions of mRNAs. AREs signal degradation of mRNAs as a means to regulate gene expression, thus by binding AREs, the ELAVL family of proteins play a role in stabilizing ARE-containing mRNAs. This gene has been implicated in a variety of biological processes and has been linked to a number of diseases, including cancer. It is highly expressed in many cancers, and could be potentially useful in cancer diagnosis, prognosis, and therapy. [provided by RefSeq, Sep 2012].
These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service.
OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
* Delivery time in business days.Occasional delay may occur due to complexity of the constructs.
The use of this shRNA has been cited in the following citations:
Posttranscriptional Suppression of Proto-Oncogene c-fms Expression by Vigilin in Breast Cancer, Ho-Hyung Woo, Xiaofang Yi, Tiffany Lamb, Ina Menzl, Terri Baker, David J. Shapiro, and Setsuko K. Chambers,
Mol. Cell. Biol., Jan 2011; 31: 215 - 225
 Post-Transcriptional Suppression of Proto-Oncogene c-fms Expression by Vigilin in Breast Cancer, Ho-Hyung Woo, Xiaofang Yi, Tiffany Lamb, Ina Menzl, Terri Baker, David J. Shapiro, and Setsuko K. Chambers,
Mol. Cell. Biol., Oct 2010; 10.1128/MCB.01031-10
[ELAVL1] Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer, H-H Woo, Y Zhou, X Yi, C L David, W Zheng, M Gilmore-Hebert, H M Kluger, E C Ulukus, T Baker, J B Stoffer, S K Chambers,
Oncogene (19 Jan 2009), doi: 10.1038/onc.2008.469
* Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping